Bridgefront Capital’s Blueprint Medicines BPMC Stock Holding History

Bridgefront Capital’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,276	Closed	-$548K	–	606
2025 Q2	$548K	Buy	+4,276	New	+$444K	0.15%	256
2025 Q1	–	Sell	-3,603	Closed	-$314K	–	635
2024 Q4	$314K	Sell	3,603 -2,460	-41%	-$225K	0.11%	343
2024 Q3	$561K	Buy	+6,063	New	+$602K	0.22%	153
2021 Q3	–	Sell	-3,915	Closed	-$344K	–	359
2021 Q2	$344K	Buy	+3,915	New	+$359K	0.13%	295
2021 Q1	–	Sell	-3,476	Closed	-$390K	–	688
2020 Q4	$390K	Buy	+3,476	New	+$366K	0.13%	282

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bridgefront Capital's BPMC Position: Q3 2025 in Review

Bridgefront Capital sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 4,276 shares — an estimated $548K sold.

Bridgefront Capital first reported a position in BPMC in Q4 2020 and held it in 5 quarters. The position peaked at $561K in Q3 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Bridgefront Capital reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Bridgefront Capital sold 4,276 Blueprint Medicines shares in Q3 2025, an estimated $548K.
Bridgefront Capital first reported a position in Blueprint Medicines in Q4 2020 and held it in 5 quarters.
Bridgefront Capital's Blueprint Medicines position peaked at $561K in Q3 2024.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Bridgefront Capital's 13F filing for Q3 2025, filed 14 Nov 2025.